Phase II clinical trial for the Alzheimer's Disease drug

June 9, 2014

Fujifilm Holdings Corporation is to accelerate the development of the Alzheimer's Disease drug "T-817MA" following the commencement of a Phase II clinical trial in late May by its group company, Toyama Chemical, in Japan. In the United States, Fujifilm Corporation entered into a partnership with the Alzheimer's Disease Cooperative Study (hereinafter "ADCS"), the largest Alzheimer's Disease therapeutic research consortium in the United States, to start a joint phase II clinical trial in June.

The number of dementia patients is estimated to be 44 million worldwide, and the figure is projected to reach 76 million by 2030. More than half of them suffer from Alzheimer's Disease, and the trend is set to continue. The drugs currently available in the market for treating Alzheimer's Disease include acetylcholinesterase inhibitors, such as donepezil hydrochloride. Since these drugs merely address the deficit in neurotransmission to give temporary improvement to the patients' symptoms, there has been a strong call for the development of a new class of therapies to treat Alzheimer's Disease.

T-817MA is an Alzheimer's Disease drug discovered by Toyama Chemical. It offers powerful protection for neurons, promotes neurite outgrowth, and has demonstrated strong efficacy in animal models.

In Japan, Toyama Chemical launched a phase I clinical trial in 2012, confirming the safety and tolerability of the T-817MA. In order to examine T-817MA's efficacy and dose response, they moved on to a phase II clinical trial, in late May, on Alzheimer patients being treated with donepezil hydrochloride. In the United States last year, Fujifilm decided to conduct a phase II clinical trial jointly with the ADCS, which has extensive experience in the field of Alzheimer's Disease therapeutic research. The phase II clinical trial began in June this year, using the same method and dosage adopted in the Japanese trial. The development of T-817MA will continue to be promoted under a clinical trial structure using the same methodology and dosage in both Japan and the United States.

There are high expectations for T-817MA as a revolutionary therapy that could deliver a high level of treatment efficacy to Alzheimer's Disease sufferers, who are rapidly increasing in our aging society. The Fujifilm Group is committed to further accelerating the development of T-817MA through joint research with the Kyoto University Center for iPS Cell Research and Application, in which patient-derived iPS cells are used to identify biomarkers that can predict the efficacy of the T-817MA.

Explore further: Drug therapy halts clinical progression in Alzheimer patients

Related Stories

Drug therapy halts clinical progression in Alzheimer patients

June 4, 2014
AFFiRiS announced today the results of a phase II study in Alzheimer patients. AFFiRiS' proprietary compound AD04 is the first drug ever to demonstrate clinical and biomarker effects consistent with disease modification in ...

Lilly stops mid-stage Alzheimer's drug study (Update)

June 13, 2013
Eli Lilly and Co. said Thursday that it stopped a mid-stage clinical trial of an experimental Alzheimer's disease drug because of potential side effects on patients' livers.

U.S. launches extensive Alzheimer's studies

January 14, 2013
(HealthDay)—Four U.S. government-funded clinical trials will search for new therapies for Alzheimer's disease.

Alzheimer's prevention trial to evaluate, monitor participants' reactions to learning of higher disease risk status

March 19, 2014
A new clinical trial will soon begin testing whether early medical intervention in people at risk for Alzheimer's can slow down progression of disease pathology before symptoms emerge, as outlined in Science Translational ...

Inherited Alzheimer's damage greater decades before symptoms appear

March 7, 2014
(Medical Xpress)—The progression of Alzheimer's may slow once symptoms appear and do significant damage , according to a study investigating an inherited form of the disease.

Pfizer and J&J end development of Alzheimer's drug

August 6, 2012
Pfizer Inc. and Johnson & Johnson say they are ending development of a once-promising drug designed to treat Alzheimer's disease after the treatment failed in two late-stage clinical trials.

Recommended for you

Lifestyle changes to stave off Alzheimer's? Hints, no proof

July 20, 2017
There are no proven ways to stave off Alzheimer's, but a new report raises the prospect that avoiding nine key risks starting in childhood just might delay or even prevent about a third of dementia cases around the world.

Blood test identifies key Alzheimer's marker

July 19, 2017
A new study led by researchers at Washington University School of Medicine in St. Louis suggests that measures of amyloid beta in the blood have the potential to help identify people with altered levels of amyloid in their ...

Steering an enzyme's 'scissors' shows potential for stopping Alzheimer's disease

July 19, 2017
The old real estate adage about "location, location, location" might also apply to the biochemical genesis of Alzheimer's disease, according to new research from the University of British Columbia.

Brain scans may change care for some people with memory loss

July 19, 2017
Does it really take an expensive brain scan to diagnose Alzheimer's? Not everybody needs one but new research suggests that for a surprising number of patients whose memory problems are hard to pin down, PET scans may lead ...

Can poor sleep boost odds for Alzheimer's?

July 18, 2017
(HealthDay)— Breathing problems during sleep may signal an increased risk for Alzheimer's disease, a trio of studies suggests.

Hearing is believing: Speech may be a clue to mental decline

July 17, 2017
Your speech may, um, help reveal if you're uh ... developing thinking problems. More pauses, filler words and other verbal changes might be an early sign of mental decline, which can lead to Alzheimer's disease, a study suggests.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.